Sun Pharmaceutical Industries Ltd Q2 Profit Seen Near ₹3,118 Crore

Sun Pharmaceutical Industries Ltd is scheduled to announce its July-September 2026 quarter results on October 30, with consensus estimates indicating revenue of about ₹15,766 crore and net profit around ₹3,085 crore to ₹3,118 crore. The figures point to revenue growth but potential pressure on operating margins from research and development spending and US generics pricing.

When will Sun Pharma announce its Q2 FY27 results?

Sun Pharma is scheduled to place its Q2 FY27 results before the board on Friday, October 30, 2026. The results cover the quarter ended September 30, 2026, and the company’s earnings presentation and investor call are expected on the same day at around 6:30 PM IST.

The reporting date comes earlier than the corresponding quarter last year. Sun Pharma announced Q2 FY26 results on November 5, 2025. The October 30 announcement will provide investors with the next reported update after Q1 FY27, when the company posted revenue of ₹15,299 crore and net profit of ₹2,910 crore.

The Q2 release is important because it will show whether the company has maintained the momentum seen in the June quarter. Q1 FY27 revenue increased 10.5% year on year, while net profit rose 27.0%, according to the reported quarterly snapshot. Its operating margin in that quarter stood at 28.9%.

What are the Q2 FY27 revenue and profit estimates for Sun Pharma?

Sun Pharma is expected to report moderate year-on-year revenue growth in Q2 FY27, with estimates broadly ranging from 9% to 11.5%. One consensus estimate places revenue at ₹15,769 crore, while another projects revenue of ₹15,766 crore, up 9% from ₹14,478 crore in Q2 FY26.

Profit estimates differ across the information provided. The broader consensus puts consolidated net profit at about ₹3,118 crore, broadly flat year on year. Another estimate expects net profit to decline 1% to ₹3,085 crore from ₹3,118 crore a year earlier. A separate range places profit between ₹3,118 crore and ₹3,180 crore.

The differences underline that the market will focus not only on reported revenue but also on the composition of profit and operating costs. EBITDA forecasts range from ₹4,403 crore to ₹4,761 crore, while one consensus estimate is ₹4,429 crore. Margin expectations similarly vary, reflecting uncertainty over spending and product-market conditions.

Why could Sun Pharma's operating margin face pressure?

Sun Pharma’s operating margin could face pressure from higher research and development expenditure, input costs and US generics pricing. Estimates place Q2 FY27 EBITDA margin between 26.3% and 29.3%, below the 31.3% margin reported a year earlier. Another estimate projects a margin of 27.9%.

Research and development spending is estimated at 6.5% of sales. The company is also expected to incur higher spending related to new drug launches, which is a relevant variable for operating profitability even if revenue continues to rise. The provided estimates do not indicate a change in the company’s reported full-year revenue outlook.

In Q2 FY26, Sun Pharma reported revenue growth of 8.86% to ₹14,478 crore, EBITDA growth of 14.90% to ₹4,527 crore and net profit of ₹3,118 crore, up 2.57%. The EBITDA margin expanded by 167 basis points to 31.27% in that period. Therefore, the year-on-year comparison for the September 2026 quarter includes a relatively high margin base.

How do India and US operations shape Sun Pharma's outlook?

Sun Pharma’s India business remains a major contributor to its sales base, while the US business is exposed to generic competition and pricing pressure. In FY26, India formulations contributed ₹19,290 crore, or 33% of gross sales, and the company held an 8.4% domestic market share. US formulations accounted for 29% of FY26 sales.

The company’s Q1 FY27 performance showed divergent regional trends. India sales rose 16% year on year, while US sales declined 9.7% because of generic competition. Innovative medicines grew 12.8% to $351 million in that quarter, supporting the company’s mix of India formulations, US formulations and specialty products.

Sun Pharma reported FY26 gross sales of ₹58,220 crore and EBITDA of ₹17,731 crore, representing a 30.3% margin. Innovative Medicines accounted for 22% of sales in FY26, compared with 7.3% in FY18, with 29 marketed products globally. The company has said it expects high single-digit overall revenue growth in FY27.

What will investors assess in Sun Pharma's Q2 results?

Investors will assess whether Sun Pharma’s revenue growth has remained aligned with its high single-digit FY27 guidance and whether India growth and innovative medicines have offset pressure in US generics. The reported results will also clarify which of the varied revenue, EBITDA and profit estimates is closest to the company’s actual performance.

Margin movement will be a central measure because Q2 FY26 had a 31.3% EBITDA margin, whereas current estimates suggest contraction. Investors will be able to compare research and development costs, input-cost effects and operating profitability against the company’s June-quarter margin of 28.9%.

For the pharmaceutical sector, the result will offer a current data point on domestic market demand, US pricing conditions and the financial impact of specialty and innovative medicine businesses. The available information anticipates Indian market growth of 9% to 12%, but it does not provide a confirmed Q2 FY27 segment-wise sales outcome before the scheduled announcement.

Conclusion

Sun Pharma enters its Q2 FY27 result announcement with consensus expectations of revenue close to ₹15,766 crore and net profit near ₹3,085 crore to ₹3,118 crore. The estimates indicate continued sales growth, but they also suggest that profitability may be affected by higher research and development expenditure, input costs and US generics pricing.

The next key event is the board meeting and earnings call on October 30, 2026. Investors will watch the company’s reported EBITDA margin, India and US sales trends, innovative medicines performance, and any update to its high single-digit revenue growth guidance for FY27.